New Research Confirms Role of LRRK2 in Immune Cells

Monday, 10 April 2017

Though associated with only a small percentage of total Parkinson’s cases, mutations of the LRRK2 gene are the greatest known genetic contributor to Parkinson’s disease (PD). Researchers are striving to understand the mechanisms of disease related to this mutation because…

Parkinson's research

Another Leap Forward for LRRK2 Development

Monday, 29 August 2016

Denali Therapeutics — a San Francisco biotech that launched last year focused on neurodegenerative diseases including Parkinson’s — recently announced it has licensed LRRK2 inhibitor compounds from Genentech. These drug candidates may address the dysfunction seen with LRRK2 mutations, the greatest…

Scientists Find New Marker to Measure LRRK2 Activity

Scientists Find New Marker to Measure LRRK2 Activity

Tuesday, 18 December 2012

The protein leucine-rich repeat kinase 2, or LRRK2, is fast becoming a target of major interest for researchers looking to develop Parkinson’s disease (PD) drugs, for a couple of reasons: For one, mutations in the gene associated with LRRK2 are…